iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the 40th Annual J.P. Morgan Conference on January 11, 2022, at 11:15 a.m. ET. The presentation will focus on the company's advancements in immuno-oncology therapeutics. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event. iTeos is developing innovative therapies, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing anti-cancer responses.
- None.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Conference being held virtually on Tuesday, January 11, 2022 at 11:15 a.m. ET.
A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
When is iTeos Therapeutics presenting at the J.P. Morgan Conference?
How can I watch the iTeos Therapeutics presentation?
What is the main focus of iTeos Therapeutics at the conference?
What products are iTeos Therapeutics currently developing?
Where is iTeos Therapeutics headquartered?
